Search:
Filter:
Sort:
What if your tirzepatide shipment came from a Brazilian beauty clinic? Or a vial of semaglutide was manufactured, supposedly, at a Costco in Toronto? In April and May 2025, dozens of shipments of semaglutide, tirzepatide, apixaban, and antibiotics entered the U.S. from facilities that aren’t in the FDA’s drug manufacturing database. These aren’t low-volume personal-use shipments; we looked at freight-scale…
Read More
We’ve published the final document of best practices for online pharmacy-to-pharmacy marketplaces.
Read More
The Partnership for Safe Medicines (PSM) today announced its strong support for the reintroduction of the Cooper Davis Devin Norring Act, a bipartisan effort aimed at curbing the online sale of deadly counterfeit and illicit drugs.
Read More
A policy change announced by U.S. Customs and Border Protection means that all FDA-regulated products are now subject to inspection at ports of entry.
Read More
503B outsourcing facilities make our drug supply more resilient, but 81% of 503Bs newly registered since June 2021 have never been inspected by FDA staff. Learn why we recommend changes to this important program.
Read More
Pill presses and molds are used to make fake pills with deadly consequences thousands of people every year. The number of Americans that take fake pills annually without a fatal event is even higher. Read our January through June 2025 report covering pill press seizures, policy developments, and legislation.
Read More
Prescription Drug Affordability Board Activity, June 2025 Activities Summary Colorado: Colorado’s next PDAB meeting will be held on August 22, 2025. Maryland: Maryland’s PDAB met on June 23 for updates about federal drug pricing and Maryland’s biotech and life sciences industry. Oregon: At its June 18 meeting, Oregon’s PDAB reviewed survey data and narrowed its list of drugs for affordability…
Read More
Avanish Kumar Jha and Rajnish Kumar Jha got 30-month sentences for selling counterfeit medicines—including vials of fake Keytruda—to U.S. buyers.
Read More
After a November 2024 inspection, the FDA issued a Form 483 to Empower Clinic Services highlighting violations related to compounded drug manufacturing practices at its East Windsor, New Jersey facility.
Read More
United States District Court Western District of Washington USA v Avanish Kumar Jha and Rajnish Kumar Jha Indictment Filed July 2025 Read the document.
Read More